The intestinal cytochrome P450 3A and P-glycoprotein: Barriers to drug absorption

Chinese Pharmacological Bulletin

Volumn 19, Issue 9, 2003, Pages 988-991

  Wang, Kun ^a   Zhong, Lai Fu ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

CYP3A; CYP3A4; Cytochrome P450 (CYP450); Gut; Oral bio availability; P glycoprotein

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DRUG; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME MECHANISM; ENZYME SPECIFICITY; GASTROINTESTINAL TRACT; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE CELL; INTESTINE VILLUS; NONHUMAN;

EID: 0242354862     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Higgins CF. ABC transporters: From microorganisms to man. Annu Rev Cell Biol, 1992;8:67-113
2. Schinkel AH, Smit JJ, van Tellingen O et al. Disrupion of the mouse mdr1a P-glycopreotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 1994;77:491-502
3. Schumacher U, mollgard K. The multidrug-resistance P-glycoprotein (P-gp, MDR1) 1 an early marker of blood-brain barrier development in the microvessels of the developing of human brain. Histochem Cell Biol, 1997;108:179-82
4. Hoffermeyers S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA, 2000;97:3473-8
5. Parreboom A, Van Asperen J, Mayer U et al. Limited oral bioavailability and active eothelial excertion of paclitaxel(Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA, 1997;94:2031-5
6. Meerm Terwogt JM, Beijnen JH, ten Bokkel Huinink WW et al. Co-adiministration of cyclosporin enables oral therapy with paclitaxel. Lancet, 1998;352:285
7. Kim Rb, Fromm MF, Wandel C et al. The drug transporter P-glycoprotein limits oral absoption and brain entry of HIV-1 protease inhibitors. J Clin Invest, 1998;101:289-94
8. Schellen JHM, Malingre MM, Kruijtzer CMF et al. Modulaton of oral bioavailability of anticancer drugs: From mouse to man. Eur J Pharma Sci, 2000;12:103-10
9. Bent LZ, Kroetz DL, Sheiner LB. Pharmacokkinetics: The dynamics of drug absorption, distribution, and elimination. In: Hardman JH, Limbird LE, Molinoff PB, et al., editors. Goodman & Gilman's the pharmacological basis of therapetics. New York: McGraw-Hill, 1996:3-28
10. Wacher VJ, Silverman JA, Zhang Y et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidominetics. J Pharm Sci, 1998;87:1322-30
11. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog, 1995;13:129-34
12. Shuetz EG, Shinkel AH, Relling MV et al. P-glycoprotein, a major determinant of rifampicin-inducible expression of cytochrome P450 3A in mice and humans. Proc Natl Acad Sci USA, 1996;93:4001-5
13. Tidefott U, Liliemark J. P-glycoprotein inhibitor vaslpodar PSC (833) increases the intracellular concentration of Daunorubicin in vivo: In patients with P-glycoprotein-positive acute myeloid leukemia. J Clin oncol, 2000;18:1837-44
14. Benet LZ, Izumi T, Zhang Y et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Controlled Release, 1999;62:25-31
15. Thummel KE, Oŗhea D, Paine MF et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A/CYP3A4-mediated metabolism. Clin Pharmacol Ther, 1996;59:491-502
16. Palkama VJ, Ahonen J, Neuvonen PJ et al. Effects of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther, 1999;66:33-9
17. Kolars JC, awmi WM, MERION rm et al. First-pass metabolism of cyclosporine by the gut. Lancet, 1991;338:1488-90
18. Lwn KS, Mayo RR, Leichtman AB et al. Role of intestinal P-glycoprotein(mdr1) in interpatient variation in the oral bioavailability of cyclosporinr A. Clin Pharmacol Ther, 1997;62: 248-60
19. Greiner B, Eichelbaum M, Fritz P et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest, 1999;104:147-5